Abstract
Objective The balance of cross-frequency coupling (CFC) over within-frequency coupling (WFC) can build a nonlinearity index (NI) that encapsulates the over-excitation of information flow between brain areas and across experimental time. The present study investigated for the very first time how the Greek High Phenolic Early Harvest Extra Virgin Olive Oil (HP-EH-EVOO) versus Moderate Phenolic (MP-EVOO) and Mediterranean Diet (MeDi) intervention in people with Mild Cognitive Impairment (MCI) could affect their spontaneous EEG dynamic connectivity.
Methods Fourty three subjects (14 in MeDi, 16 in MP-EVOO and 13 in HP-EH-EVOO) followed an EEG resting-state recording session (eyes-open and closed) before and after the treatment. Following our dominant coupling mode model (DoCM), we built a dynamic integrated dynamic functional connectivity graph (iDFCG) that tabulates both the functional strength and the DoCM of every pair of brain areas.
Results Signal spectrum within 1-13 Hz and theta/beta ratio have been decreased in the HP-EH-EVOO group in both conditions. FIDoCM has been improved after the intervention across groups and conditions but was more prominent in HP-EH-EVOO group (p < 0.001). Finally,we revealed a significant higher post-intervention reduction of NI (ΔNITotal and α) for the HP-EH-EVOO compared to the MP-EVOO and MeDi groups (p < 0.0001).
Conclusions Long-term intervention with HP-EH-EVOO reduced the over-excitation of information flow in spontaneous brain activity.
Significance Our study confirms the alteration of signal spectrum of EEG rhythms and dominant coupling mode due to the intervention with HP-EH-EVOO nutrition protocol.
Highlights
Non-pharmaceutical intervention based on HP-EH-EVOO in MCI reduces the over-excitation of information flow
Non-pharmaceutical intervention based on HP-EH-EVOO in MCI increases the human brain flexibility
Reconfiguration of dominant coupling modes in EEG resting-state due to the intervention is modulated by alpha frequency
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
https://clinicaltrials.gov/ct2/show/NCT03362996
Clinical Protocols
https://clinicaltrials.gov/ct2/show/NCT03362996
Funding Statement
This work has been supported by the Greek Association of Alzheimers Disease and Related Disorders (GAADRD), the World Olive Centre for Health (WOCH) and Yannis Olive Grove company for the donation of HP-EH-EVOO: Yannis Fresh and MPEVOO: Yannis Selected. In addition, we would like to thank Panagiotis Diamantakos and Aimilia Riga kou for technical support in the analysis of EVOO, Hadar Halivni for editing the English language, and all clinicians who contributed to this study, as well as patients who took part in it. SD was supported by a MRC grant MR/K004360/1 (Behavioural and Neurophysiological Effects of Schizophrenia Risk Genes: A Multi-locus, Pathway Based Approach) and a MARIE-CURIE COFUND EU-UK Research Fellowship.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The MICOIL study was realised in accordance with the Declaration of Helsinki and was approved by the GADRDA scientific & ethics committee (25/ 240 2016) (Clinical Trials Registration Number: NCT03 241 362996). All participants fulfilled the Petersen criteria for MCI (Petersen et al., 2009). The program of experiments has been approved by the local ethical committee of Alzheimer Hellas (no. 25/21-6-2016).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
I have added the last author.
Data Availability
The dataset is not available to the public.
